HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.64; value investors ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

NASDAQ HALO opened at $58.29 on Friday ... The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business’s 50-day simple moving average ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce ...

Analog Devices led chips stocks higher on Wednesday after its results kept analysts bullish, while Lam Research (LRCX) made key announcements alongside its investor day.

Lam Research was upgraded to Positive from Neutral by the analysts at Susquehanna following its Investor Day in New York City on Wednesday.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated ...

S&P 500 E-Mini futures (ESH25) are up +0.28%, andMarch Nasdaq 100 E-Mini futures (NQH25) are up +0.36% this morning, with ...